Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...
EGFR drug ALX2004 and evorpacept, which recently showed activity with Jazz's Ziihera in CD47- and HER2-positive breast cancer.
The agency previously declined to approve the application for UX111, citing issues related to chemistry, manufacturing, and controls (CMC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results